Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2021 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets

—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...
July 01, 2021 16:15 ET | Source: BioCryst Pharmaceuticals, Inc.

ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress

RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy...
June 16, 2021 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health

RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has accepted the regulatory...
May 06, 2020 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones

—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in...
June 27, 2019 16:15 ET | Source: BioCryst Pharmaceuticals, Inc.

Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases

—Data expected in Q4 2019— —BCX9930 showed high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— RESEARCH TRIANGLE PARK, N.C., June 27, 2019 (GLOBE...
February 28, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Barclays Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare...
February 18, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4

RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2018...
November 20, 2018 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. ...
November 06, 2018 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Third Quarter 2018 Financial Results

APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced...